Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda buys Abbott’s stake in TAP

Executive Summary

Japanese drug maker Takeda will be the sole owner of TAP Pharmaceutical Products after the firm finalizes a deal March 19 to buy Abbott's share of the 50/50 joint venture. When the transaction closes, TAP will be integrated into Takeda Pharmaceuticals North America and Takeda Global Research & Development Center, with the two reporting to a newly established Takeda America Holdings. Takeda says the deal will make the company a top 15 pharmaceutical company in the U.S. As part of the deal, Abbott and Takeda will evenly divide the value of the joint venture, with Abbott maintaining the rights to the prostate cancer drug Lupron (leuprolide acetate). Takeda gets rights to the only other TAP-marketed product - the heartburn and gastro-esophageal reflux medication Prevacid (lansoprazole)

You may also be interested in...

Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade

Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion

Health And Wellness Weekly Trademarks Review: 9 August

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Senate Cannabis Bill Could Torch US Hemp Market By Slashing THC Limit Below Farm Bill Level

Hemp Roundtable says Cannabis Administration and Opportunity Act’s limit of 0.001% THC per 100 g by dry weight for ingredients derived from cannabis to qualify as hemp “would impose a devastating setback to a thriving industry, and further limit opportunities for already struggling hemp farmers.”

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts